9th Spring Meeting

  • Sponsors:
  • Exhibits:

  • Additional Support:
  • Media Partners:


  • Lawrence C. Thompson, PhD

    Principal Scientist and Group Leader, BioTherapeutics Pharm Sci, Analytical Research and Development

    Pfizer, Inc.

    Process Development and Analytical Characterization of the Adenovirus and Plasmid Components for the Vaccine-Based Immunotherapy Regimen

  • Young Jik Kwon, PhD

    Professor, Department of Pharmaceutical Sciences; Department of Chemical Engineering and Materials Science

    University of California, Irvine (UCI)

    Chemically Induced Extracellular Vesicles for Versatile Therapies via Facile and Scalable Production and Purification

  • Jacques Galipeau, MD

    Associate Dean for Therapeutics Development; Director, Program for Advanced Cell Therapy

    University of Wisconsin-Madison

    Cellular Cryoinjury and Potency – the Mesenchymal Stromal Cell Paradigm

  • Peter Gagnon

    Chief Scientific Officer

    BIA Separations

    Emerging Methods for Exosome Purification and Process Monitoring

  • Mania Ackermann, PhD

    Postdoctoral Fellow, Project Leader, REBIRTH Unit, Translational Hematology of Congenital Diseases, Institute of Experimental Hematology

    Hannover Medical School

    iPSC Technology: New Avenues for Blood Farming and Cell-Based Therapies

  • Christoph Geisler, PhD

    Chief Research Scientist

    GlycoBac LLC

    News on Sf-Rhabdovirus Biology and Host Range

  • Hazel Aranha, PhD

    Virus Safety and Clearance, SME

    Sartorius Stedim North America Inc.

    Raw Materials Management: A Cornerstone for Risk Mitigation in Virus Safety Assurance of Biopharmaceuticals

  • Peter Pushko, PhD

    President and Chief Scientific Officer

    Medigen, Inc.

    Development of Multi-Subtype VLPs (msVLPs) as Broadly Protective Influenza Vaccines

  • Karen Doucette

    Director of Operations

    ACF Bioservices

    Validating GMP-Compliant In Vitro Relative Potency Assays for Cell and Gene Therapy Products

  • Alfred Luitjens

    Director Cell Technology

    Batavia Biosciences

    Highly Intensified, Low-Cost Vaccine Manufacturing Platform

  • Daniel S. Hurwit

    Senior Associate Engineer

    Voyager Therapeutics

    Optimization of the Harvest and Clarification Steps for Purification and cGMP Manufacture of Sf9/Baculovirus-Derived rAAV Vectors

  • Romy M. Dalton, PhD

    Chief Operations Officer

    Algenex, Inc.

    Highly Efficient Production of VLP-Based Vaccines by a Bioreactor-Free Novel BEVS Technology

  • Monique M. van Oers, PhD

    Professor, Laboratory of Virology

    Wageningen University

    Walking with Insects: How Viruses Manipulate Insect Behaviour

  • Ajaykumar Maghodia, PhD

    Research Scientist

    University of Wyoming

    Creation and Characterization of a New Generation of Glycoengineered Baculovirus Vectors

  • Laura A. Palomares, ScD

    Researcher and Professor

    Universidad Nacional Autónoma de México (UNAM)

    AAV and Baculovirus Vectors for the Treatment of Hyperammonemia Caused by Liver Failure

  • Yue "Joyce" Zhao, PhD

    Director, Analytical Development

    bluebird bio Inc.

    Quantitative Analysis of Lentiviral Vector Potency for Gene Therapy in Hemoglobinopathies

  • David A. Theilmann, PhD

    Senior Research Scientist, Summerland Research and Development Centre

    Agriculture and Agri-Food Canada

    Role of Viral Ubiquitin Ligases and Viral Ubiquitin in Autographa Californica Nucleopolyhedrovirus (AcMNPV) Replication and Virion Production

  • Sangeetha L. Sagar, PhD

    Head Global Innovation Technology & Quality

    Sanofi Pasteur

    Accelerating Vaccine Development

  • Eva Rohde, MD

    Head of University Clinic for Blood Group Serology and Transfusion Medicine; Director of GMP Laboratory

    Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU)

    The Therapeutic Potency of Stromal Cell Derived Extracellular Vesicles

  • Chun Fang Shen, PhD

    Senior Research Council Officer, Cell Culture Scale-up, Life Sciences, NRC Human Health Therapeutics Research Center

    National Research Council Canada (NRC)

    Development of Suspension-Adapted Vero Cell Culture Technology for Viral Vaccine Production

  • Marylou G. Gibson, PhD

    General Manager and Chief Scientist

    Virapur, LLC

    Screening Egg and Tissue Culture Platforms for Influenza Virus Yield and Characteristics

  • Gregory F. Alberts, PhD

    Global Subject Matter Expert, Pharma Bioscience Solutions

    Lonza Walkersville, Inc.

    Non-Viral Transfection and Genome Editing: Bench to Clinic to Commercial

  • Michael Day, PhD

    Director, Regulatory Science; Co-Head Advanced Therapeutics

    Voisin Consulting Life Sciences

    Regulatory and Development Strategies for Gene and Cell Therapies

  • Henry de Malmanche

    PhD Candidate

    University of Queensland

    Baculovirus Biopesticides: Progress Towards Reaching Commercially Viable Yields of Bioreactor-Produced Occlusion Bodies by Exploring Gene Knock-Ins and CRISPR/Cas9 Knock-Outs of Production Cell Lines

  • Chia-Hsing Pi

    PhD Candidate

    University of Minnesota

    Using Interactions Between Solutes to Improve Preservation of Lymphocytes

  • Lindsey Ott, PhD

    Director of Product Innovation

    Likarda, LLC

    3D In Vitro Screening for Cancer Immunotherapies

  • Olli H. Laitinen, PhD

    Adjunct Professor, University Researcher

    University of Tampere

    Optimizing the Baculovirus Expression System for Coxsackievirus VLP-Vaccine Production

  • Johan Skog, PhD

    Chief Scientific Officer

    Exosome Diagnostics, Inc.

    Current State of Exosome-Based Diagnostics

  • Mark Flower

    VP Business Development & Strategic Relationships

    Be The Match BioTherapies, National Marrow Donor Program (NMDP)

    Mitigating Supply Chain Challenges in Cell Therapies, and the Importance of Quality Apheresis — A Critical Starting Material

  • Andrew Quigley

    Membrane Protein Laboratory Coordinator/ Group Leader

    Diamond Light Source Ltd

    The Baculovirus-Based Over-Expression of Membrane Proteins for Structural Biology

  • Francis Karanu, PhD

    Director of Animal Health & Senior Scientist

    Likarda, LLC

    Comparing Characterization Assays Across Different Cell Therapies

  • Aaron C. Mack

    Engineer III, Materials Science


    Upstream Viral Risk Mitigation Approach: Next-Generation Manufacturing

  • Darren W. Begley

    Sr. Scientist, Analytical Development

    Ultragenyx Pharmaceutical

    Evaluating Light-Scattering Methods for AAV Characterization

  • Christine Le Bec, PhD

    Head of CMC Analytical


    Strategies and Advances in AAV Vector Characterization: Product-Related Impurities

  • Imre Berger, PhD

    Professor & Director, Bristol Synthetic Biology Research Centre (BrisSynBio)

    University of Bristol

    MultiBac: From Multiprotein Complex Structures to Synthetic Viral Nanosystems (SVNs)

  • Suitability and Perspectives of Different Insect Cell Factories for the Production of Antimicrobial Peptides

  • Katrina Adlerz, PhD

    Scientist, Analytical Development

    RoosterBio Inc.

    Manufacturing Solutions Driving Rapid Clinical Translation of hMSCs

  • Cenk Sumen, PhD

    Director, Business Development, BioProduction Division

    Thermo Fisher Scientific

    T-cell Therapies: Building the Next Operating System

  • Willem "Wian" A. de Jongh, PhD


    ExpreS2ion Biotechnologies

    Development of Drosophila S2-Based Vaccine Production Processes

  • Anna Kwilas, PhD

    Product CMC Reviewer, Gene Therapy Branch, Division of Cellular & Gene Therapies, Office of Tissue & Advanced Therapies


    Regulatory Updates for Virus-Based Human Gene Therapy Products

  • Arifa S. Khan, PhD

    Principal Investigator/Supervisory Microbiologist, Office of Vaccines Research and Review


    Updated Evaluation of the Sf9 Cell Line

  • Amanda K.A. Silva

    CNRS Researcher

    Université Paris Diderot

    Triggering High-Yield Extracellular Vesicle Production for Regenerative Medicine

  • Eun Tack "Kevin" Hwang

    Associate Process Engineer – Gene Therapy Manufacturing Technical Services

    Pfizer, Inc.

    Overview of Recombinant Adeno-Associated Virus (rAAV) Production and Challenges in Development and Manufacturing Scale

  • Inês A. Isidro, PhD

    Scientist - Computational Biotechnology, Animal Cell Technology Unit

    Instituto de Biologia Experimental e Tecnológica (iBET)

    Metabolic Modulation of Insect Cells by Baculovirus Infection: Insights for Bioprocess Optimization

  • Ivan Wall, PhD

    Professor of Regenerative Medicine, Cell and Gene Therapy Bioprocessing, School of Life & Health Sciences

    Aston University

    Bioprocessing of Cells and Exosomes for Regenerative Medicine

  • Cyril G. Gay, DVM, PhD

    National Program Leader, Animal Production and Protection, Agricultural Research Service (ARS), Research, Education, and Economics

    US Department of Agriculture

    Foot-and-Mouth Disease Vaccine Platform for Safe Production in the USA: FMDV-LL3B3D

  • Jan Joseph "Jos" Melenhorst, PhD

    Director, Product Development & Correlative Sciences Laboratories; Adjunct Associate Professor, Pathology & Laboratory Medicine

    University of Pennsylvania

    Immunological Concepts of CAR T-Cell Therapies

  • Udo Reichl

    Director, Bioprocess Engineering

    Max-Planck-Institute for Dynamics of Complex Technical Systems

    High-Yield Viral Vaccine Production: Process Options and Monitoring

  • Development of the First World Health Organization (WHO) International Standard for Gene Therapy

  • Gale E. Smith, PhD

    Discovery & Pre-Clinical Research Chief Scientist

    Novavax, Inc.

    Baculovirus Expression System for High Level Production of Novel Full-Length Glycoprotein Nanoparticle Vaccines

  • Lois Horton

    Associate Director, Upstream Process Development, Gene Therapy Development & Manufacturing, Biologics Development

    Sanofi Genzyme

    Producer Cell Line for Gene Therapy Development

  • Brian Hampson

    VP Global Manufacturing Sciences & Technology

    Hitachi Chemical Advanced Therapeutics Solutions, LLC

    Automation in Cell Therapy — What Problem(s) are We Trying to Solve?

  • Debra A. Webster, PhD

    Director, Advanced Therapy Medicinal Product Development, Regulatory Sciences

    Cardinal Health

    Keeping Pace with Product Development: Synergies Between Quality, Nonclinical, and Clinical Programs

  • Florian Krammer, PhD

    Associate Professor

    Icahn School of Medicine at Mount Sinai

    The Influenza Virus Neuraminidase as a Vaccine Target

  • Jakob Reiser, PhD

    Principal Investigator


    Manufacturing Issues During Late-Phase Development of CAR T-cell Products

  • Leticia Frizzo da Silva, DVM, PhD

    R&D Project Leader

    Ceva Animal Health, LLC

    Turkey Herpesvirus as a Vector for Poultry Vaccines

  • Anthony Leyme, PhD

    Scientist II, Technical Development, Analytical Bioassay Development


    In Vitro Approaches to Demonstrating Potency of Gene Therapy Products

  • Robin Levis, PhD

    Deputy Director, Division of Viral Products, Office of Vaccines Research and Review


    Historical Perspectives on the Use of Diverse Cell Substrates for Viral Vaccine Manufacturing

  • Kevin P. Kent, PhD

    Scientist IV

    Boehringer Ingelheim Vetmedica, Inc.

    Multivariate Data Analysis for Reduction of Variation in a Viral Vaccine Production Process

  • Michelet Dorceus

    Senior Bioprocess Application Specialist

    Eppendorf North America

    High-Density Vero Cell Perfusion Culture in Single-Use Vessels

  • Peter Czermak

    Professor of Bioprocess/Biochemical Engineering

    Technische Hochschule Mittelhessen, Fachbereich LSE

    Oncolytic Measles Virus Manufacturing: Linking Upstream and Downstream Strategies

  • Matthew Kremer


    Matson Louise LLC

    A Low-Footprint, Intensified, Single-Use Platform for the Production of Viral Vaccines

  • Jamal Meghrous, PhD

    Manager, Upstream Process Development

    Protein Sciences Corporation, A Sanofi Company

    Baculovirus Platform for Rapid Manufacturing of Seasonal Flu Vaccine at Large-Scale